Cardiovascular Outcomes Trial
Abbreviation: CVOT
Definition
A large trial that tests whether a diabetes or metabolic drug raises or lowers the risk of major heart events such as heart attack, stroke or cardiovascular death.
Cardiovascular Outcomes Trial
A cardiovascular outcomes trial (CVOT) is a large randomized, controlled study built to measure a drug’s effect on major adverse cardiovascular events (MACE). The usual primary endpoint combines cardiovascular death, non-fatal heart attack and non-fatal stroke, often called three-point MACE. Some trials add hospitalization for unstable angina (four-point MACE). CVOTs became a regulatory requirement for new diabetes drugs after a 2008 FDA guidance document required every new glucose-lowering drug to show cardiovascular safety. Concerns about the thiazolidinedione rosiglitazone prompted that guidance.
CVOTs are usually event-driven: they run until a set number of cardiovascular events has been confirmed, however long that takes. That means enrolling thousands of people, often at high cardiovascular risk, sometimes for several years. The statistical aim is to show the drug is non-inferior to placebo (added to standard care) for MACE, with the upper bound of the 95% confidence interval for the hazard ratio below 1.3. Several incretin-based drugs have gone beyond safety and shown a statistically significant cardiovascular benefit in CVOTs, including liraglutide (LEADER trial) and semaglutide (SELECT trial).
Clinical Relevance to Retatrutide
Retatrutide’s dedicated cardiovascular outcomes trial, TRIUMPH-Outcomes (about 10,000 participants), is running and has not reported. Given the large weight loss and metabolic gains in earlier studies, researchers want to know whether retatrutide’s triple receptor action brings cardiovascular benefits beyond those of GLP-1 receptor agonists alone. Its glucagon receptor activity may help lipid metabolism and reduce liver fat, and the size of the weight loss alone should improve several cardiometabolic risk factors. CVOT results will be essential to establish retatrutide’s full clinical value for people with type 2 diabetes and obesity who are at higher cardiovascular risk.